Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Loading live signals…
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Material AgreementItem 1.01 · 8-KLOW RiskPositive
Rocket Pharmaceuticals, Inc.
rocketpharma.comFiled: Mar 10, 2026CIK: 0001281895Health Care
AI Executive Summary
AI-powered analysis of 8-K filing content
Rocket Pharmaceuticals entered into an at-the-market offering agreement with Cantor Fitzgerald to raise up to $100 million through common stock sales, providing the company with flexible capital access for operations and development.
Key Takeaways
Rocket Pharmaceuticals secured a $100 million at-the-market offering program with Cantor Fitzgerald & Co.
The offering is supported by a Form S-3 shelf registration statement filed on March 2, 2026
2 more takeaways
Filing Overview
Form Type8-K
Filing DateMar 10, 2026
Item1.01
CategoryMaterial Agreement
CIK0001281895
Accession #0001281895
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
stock offeringmaterial agreement
What This Means
The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.